VON ESCHENBACH ANDREW C.

SEC source: 0001193125-26-343029 · ownership.xml · nonDerivative · entry 2

VON ESCHENBACH ANDREW C. · CIK 0001536529 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,733

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.57 to $16.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

F3 · balance_after: Reflects the exempt forfeiture to the Issuer of 4,364 matching restricted share units ("MRSUs") for no consideration in connection with the reporting person's resignation from the Board of Directors of the Issuer on August 5, 2026, in accordance with the terms of such MRSUs.

SEC source: 0001193125-26-343029 · ownership.xml · nonDerivative · entry 1

VON ESCHENBACH ANDREW C. · CIK 0001536529 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 69,792

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.43 to $16.54, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

F3 · balance_after: Reflects the exempt forfeiture to the Issuer of 4,364 matching restricted share units ("MRSUs") for no consideration in connection with the reporting person's resignation from the Board of Directors of the Issuer on August 5, 2026, in accordance with the terms of such MRSUs.

SEC source: 0001860742-26-000082 · form4.xml · nonDerivative · entry 1

VON ESCHENBACH ANDREW C. · CIK 0001536529 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 86,656

F1 · shares: Reflects the annual grant of restricted share units ("RSUs") to non-employee directors under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, as amended and restated. Vested RSUs are settled in common shares, no par value, of Bausch + Lomb Corporation. The RSUs are scheduled to vest on the date immediately preceding the conclusion of the next annual meeting of shareholders.

SEC source: 0001860742-26-000050 · form4.xml · nonDerivative · entry 2

VON ESCHENBACH ANDREW C. · CIK 0001536529 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,814

F1 · shares: Represents matching restricted share units ("MRSUs") granted to the reporting person in connection with the open market purchase of common shares reported on Table I above, pursuant to the issuer's matching share program. One-third of the MRSUs will vest on each of the first, second, and third anniversaries following the date of grant, subject to the reporting person's continued service (except in limited circumstances).

SEC source: 0001860742-26-000050 · form4.xml · nonDerivative · entry 1

VON ESCHENBACH ANDREW C. · CIK 0001536529 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,450

SEC source: 0001127602-25-015807 · form4.xml · nonDerivative · entry 1

VON ESCHENBACH ANDREW C. · CIK 0001536529 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,086

F1 · shares: Reflects the annual grant of restricted share units ("RSUs") to non-employee directors under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, as amended and restated. Vested RSUs are settled in common shares, no par value, of Bausch + Lomb Corporation. The RSUs are scheduled to vest immediately prior to the next annual meeting of shareholders.

SEC source: 0001127602-25-013477 · form4.xml · nonDerivative · entry 1

VON ESCHENBACH ANDREW C. · CIK 0001536529 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,748

SEC source: 0001415889-24-021938 · form4-08222024_120809.xml · derivative · entry 1

VON ESCHENBACH ANDREW C. · CIK 0001536529 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2034-08-12

F1 · derivative.exercise_date: The shares subject to the option shall fully vest on the one-year anniversary of the grant date of August 13, 2024, provided that the shares subject to the option will in any case be fully vested on the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person's continued service with the Issuer.

SEC source: 0001127602-24-021761 · form4.xml · nonDerivative · entry 1

VON ESCHENBACH ANDREW C. · CIK 0001536529 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,053

F1 · shares: Reflects the annual grant of restricted stock units ("RSUs") to non-employee directors under the Amended and Restated Bausch + Lomb Corporation 2022 Omnibus Incentive Plan. Vested RSUs are settled in common shares, no par value, of Bausch + Lomb Corporation. The RSUs are scheduled to vest immediately prior to the next annual meeting of shareholders.

SEC source: 0001415889-24-015617 · form4-06052024_090658.xml · derivative · entry 2

VON ESCHENBACH ANDREW C. · CIK 0001536529 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · The Vons Living Trust U/T/A 4/3/2024 dated 4/3/2024

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2033-08-09

F1 · kind: The Reporting Person transferred this option to The Vons Living Trust U/T/A 4/3/2024 dated 4/3/2024, Andrew von Eschenbach and Madelyn Giancaterino von Eschenbach, Co-Trustees (the "Trust") for no consideration. The Reporting Person and his spouse are co-trustees of the Trust, and the Reporting Person is the sole beneficiary of the Trust. The Reporting Person remains the beneficial owner of the securities held by the Trust.

F2 · derivative.exercise_date: The shares subject to this stock option vest in three equal annual installments from the vesting commencement date of August 10, 2023, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.

F1 · ownership.direct: The Reporting Person transferred this option to The Vons Living Trust U/T/A 4/3/2024 dated 4/3/2024, Andrew von Eschenbach and Madelyn Giancaterino von Eschenbach, Co-Trustees (the "Trust") for no consideration. The Reporting Person and his spouse are co-trustees of the Trust, and the Reporting Person is the sole beneficiary of the Trust. The Reporting Person remains the beneficial owner of the securities held by the Trust.

SEC source: 0001415889-24-015617 · form4-06052024_090658.xml · derivative · entry 1

VON ESCHENBACH ANDREW C. · CIK 0001536529 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 35,000 shares

Expires 2033-08-09

F1 · kind: The Reporting Person transferred this option to The Vons Living Trust U/T/A 4/3/2024 dated 4/3/2024, Andrew von Eschenbach and Madelyn Giancaterino von Eschenbach, Co-Trustees (the "Trust") for no consideration. The Reporting Person and his spouse are co-trustees of the Trust, and the Reporting Person is the sole beneficiary of the Trust. The Reporting Person remains the beneficial owner of the securities held by the Trust.

F2 · derivative.exercise_date: The shares subject to this stock option vest in three equal annual installments from the vesting commencement date of August 10, 2023, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.

SEC source: 0001209191-23-045697 · doc4.xml · derivative · entry 1

VON ESCHENBACH ANDREW C. · CIK 0001536529 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2033-08-09

F1 · derivative.exercise_date: The shares subject to this stock option vest in three equal annual installments from the vesting commencement date of August 10, 2023, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.

SEC source: 0000899243-23-015878 · doc4.xml · derivative · entry 2

VON ESCHENBACH ANDREW C. · CIK 0001536529 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 277,778

Underlying: Class A Common Stock · 277,778 shares

Expires 2033-06-14

F3 · derivative.exercise_date: This option was granted under the 2021 Plan and shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, June 14, 2023, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date.

SEC source: 0000899243-23-015878 · doc4.xml · nonDerivative · entry 1

VON ESCHENBACH ANDREW C. · CIK 0001536529 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 336,066

F1 · shares: These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan"), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, June 14, 2023, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date.

F2 · balance_after: Includes 199,921 RSUs granted under the 2021 Plan, with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, June 14, 2023, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date.

SEC source: 0001127602-23-014715 · form4.xml · nonDerivative · entry 1

VON ESCHENBACH ANDREW C. · CIK 0001536529 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,357

F1 · shares: Reflects the annual grant of restricted stock units ("RSUs") to non-employee directors under the Amended and Restated Bausch + Lomb Corporation 2022 Omnibus Incentive Plan. Vested RSUs are settled in common shares, no par value, of Bausch + Lomb Corporation. The RSUs are scheduled to vest immediately prior to the next annual meeting of shareholders.

SEC source: 0000899243-22-028637 · doc4.xml · derivative · entry 2

VON ESCHENBACH ANDREW C. · CIK 0001536529 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2032-01-14

F2 · price: Pursuant to the Merger Agreement, at the Effective Time, these options automatically vested and were cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (without interest) (A) an amount in cash (less applicable Tax withholdings) equal to the product of (x) the total number of Shares subject to such option immediately prior to the effective time multiplied by (y) the excess, if any, of the Cash Consideration over the applicable exercise price per Share under such option, and (B) one CVR for each Share subject thereto.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, these options automatically vested and were cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (without interest) (A) an amount in cash (less applicable Tax withholdings) equal to the product of (x) the total number of Shares subject to such option immediately prior to the effective time multiplied by (y) the excess, if any, of the Cash Consideration over the applicable exercise price per Share under such option, and (B) one CVR for each Share subject thereto.

SEC source: 0000899243-22-028637 · doc4.xml · nonDerivative · entry 1

VON ESCHENBACH ANDREW C. · CIK 0001536529 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Pursuant to the Merger Agreement, as of the Effective Time, these shares were converted into the right to receive the consideration per Share of (i) $10.00, payable to the holder thereof of cash, without interest but subject to reduction for any applicable withholding Taxes payable in respect thereof, and (ii) one CVR per share.

F1 · price: Pursuant to the Merger Agreement, as of the Effective Time, these shares were converted into the right to receive the consideration per Share of (i) $10.00, payable to the holder thereof of cash, without interest but subject to reduction for any applicable withholding Taxes payable in respect thereof, and (ii) one CVR per share.

SEC source: 0000899243-22-026184 · doc4.xml · derivative · entry 2

VON ESCHENBACH ANDREW C. · CIK 0001536529 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,152

Underlying: Class A Common Stock · 54,152 shares

Expires 2032-07-13

F2 · derivative.exercise_date: This option is granted under the Issuer's 2021 Plan and shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, July 13, 2022, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date.

SEC source: 0000899243-22-026184 · doc4.xml · nonDerivative · entry 1

VON ESCHENBACH ANDREW C. · CIK 0001536529 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 136,145

F1 · shares: These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan"), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs is shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, July 13, 2022, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date.

SEC source: 0000899243-22-017847 · doc4.xml · nonDerivative · entry 1

VON ESCHENBACH ANDREW C. · CIK 0001536529 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,500

F1 · shares: Reflects the grant of restricted stock units ("RSUs") under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (the "Plan"). Vested RSUs are settled in common shares, no par value, of Bausch + Lomb Corporation (the "Company").

F2 · shares: The RSUs are scheduled to vest on the date of the first regular annual meeting of the Company's shareholders in 2023, subject to the reporting person's continued service through such date.

SEC source: 0001209191-22-004790 · doc4.xml · derivative · entry 2

VON ESCHENBACH ANDREW C. · CIK 0001536529 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2032-01-14

F2 · derivative.exercise_date: This option vests in full on the first anniversary of the grant date, subject to continued service with RDUS through such date.

SEC source: 0001209191-22-004790 · doc4.xml · nonDerivative · entry 1

VON ESCHENBACH ANDREW C. · CIK 0001536529 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,500

F1 · price: The shares were acquired pursuant to a restricted stock unit award under the 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of RDUS common stock. The restricted stock units vest in full on the first anniversary of the award date, subject to continued service with RDUS through such date.

SEC source: 0000899243-21-046680 · doc4.xml · derivative · entry 2

VON ESCHENBACH ANDREW C. · CIK 0001536529 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 207,437

Underlying: Class A Common Stock · 100,000 shares

Expires 2027-06-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This option is fully vested and exercisable.

SEC source: 0000899243-21-046680 · doc4.xml · nonDerivative · entry 1

VON ESCHENBACH ANDREW C. · CIK 0001536529 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001213900-21-047735 · ownership.xml · derivative · entry 1

VON ESCHENBACH ANDREW C. · CIK 0001536529 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,053

Underlying: Class A Common Stock · 56,053 shares

Expires 2031-09-09

F1 · derivative.exercise_date: This option shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, September 9, 2021, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through each such date.

SEC source: 0001127602-21-023339 · form4.xml · nonDerivative · entry 1

VON ESCHENBACH ANDREW C. · CIK 0001536529 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,647

SEC source: 0001209191-21-047511 · doc4.xml · derivative · entry 2

VON ESCHENBACH ANDREW C. · CIK 0001536529 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 269,007

Underlying: Class A Common Stock · 269,007 shares

Expires 2031-07-16

F2 · price: Pursuant to the Merger Agreement and Plan of Merger and Reorganization, dated January 8, 2021 (the "Business Combination Agreement"), by and among GX Acquisition Corp. ("GX"), Alpha First Merger Sub Corp., Celularity LLC and Celularity Inc. ("Legacy Celularity"), each security to purchase shares of Legacy Celularity common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a 1-to-0.768594024295126 conversion ratio. Upon consummation of the business combination, GX changed its name to "Celularity Inc."

F3 · derivative.exercise_date: This Deferred Compensation Award ("DCA") shall become exercisable solely upon the first to occur of: (i) the consummation of a change of control that is also a change in the ownership or effective control of the Issuer, or in the ownership of a substantial portion of the Issuer's assets, (ii) the Reporting Person's death or disability, or (iii) March 24, 2023, subject to the Reporting Person's continuous service with the Issuer on such date.

SEC source: 0001209191-21-047511 · doc4.xml · derivative · entry 1

VON ESCHENBACH ANDREW C. · CIK 0001536529 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 307,437

Underlying: Class A Common Stock · 307,437 shares

Expires 2031-07-16

F2 · price: Pursuant to the Merger Agreement and Plan of Merger and Reorganization, dated January 8, 2021 (the "Business Combination Agreement"), by and among GX Acquisition Corp. ("GX"), Alpha First Merger Sub Corp., Celularity LLC and Celularity Inc. ("Legacy Celularity"), each security to purchase shares of Legacy Celularity common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a 1-to-0.768594024295126 conversion ratio. Upon consummation of the business combination, GX changed its name to "Celularity Inc."

F1 · derivative.exercise_date: This option is fully vested and exercisable.

SEC source: 0001127602-21-014919 · form4.xml · nonDerivative · entry 1

VON ESCHENBACH ANDREW C. · CIK 0001536529 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,247

F1 · shares: Represents the award of restricted share units ("RSUs") granted to non-employee directors of the Issuer on the third business day following their election at the Issuer's Annual Meeting of Shareholders. The RSUs have a grant date value equal to $250,000, vest immediately prior to the Issuer's next Annual Meeting of Shareholders, and are settled in common shares, no par value, of the Issuer.

SEC source: 0001209191-21-001142 · doc4.xml · derivative · entry 1

VON ESCHENBACH ANDREW C. · CIK 0001536529 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2031-01-04

F1 · derivative.exercise_date: This option shall vest in substantially equal installments on each of the first four anniversaries of January 4, 2021.

SEC source: 0001127602-20-015046 · form4.xml · nonDerivative · entry 1

VON ESCHENBACH ANDREW C. · CIK 0001536529 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,602

F1 · shares: Represents the award of restricted share units ("RSUs") granted to non-employee directors of the Issuer on the third business day following their election at the Issuer's Annual Meeting of Shareholders. The RSUs have a grant date value equal to $200,000, vest immediately prior to the Issuer's next Annual Meeting of Shareholders, and are settled in common shares, no par value, of the Issuer.

SEC source: 0001127602-20-010315 · form4.xml · nonDerivative · entry 1

VON ESCHENBACH ANDREW C. · CIK 0001536529 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,565

SEC source: 0001127602-19-017273 · form4.xml · nonDerivative · entry 1

VON ESCHENBACH ANDREW C. · CIK 0001536529 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,465

F1 · shares: Represents the award of restricted share units ("RSUs") granted to non-employee directors of Bausch Health Companies Inc. ("Bausch Health") on the third business day following their election at the Annual Meeting of Shareholders of Bausch Health (the "Annual Meeting"). The RSUs have a grant date value equal to $250,000, vest immediately prior to Bausch Health's next Annual Meeting, and are settled in common shares, no par value, of Bausch Health.

SEC source: 0001127602-18-031509 · form4.xml · nonDerivative · entry 1

VON ESCHENBACH ANDREW C. · CIK 0001536529 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,832

F1 · shares: Represents Restricted Share Units ("RSUs"), each representing a contingent right to receive one Common Share, no par value, of Bausch Health Companies Inc., which will vest immediately before the 2019 Annual Meeting of Shareholders.